Xenon Pharmaceuticals (XENE) Cash from Operations (2013 - 2026)
Xenon Pharmaceuticals (XENE) reported Cash from Operations of 88897000.0 for Q1 2026, down 44.19% year-over-year from 159289616.76 in Q1 2025, and down 9.1% quarter-over-quarter from 81481000.0 in Q4 2025.
Xenon Pharmaceuticals (XENE) Cash from Operations (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has 14 years of Cash from Operations data on file, last reported at 88897000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 88897000.0, down 44.19% year-over-year; the trailing twelve-month figure through Mar 2026 was 306363000.0 (down 55.63% YoY), and the FY2025 annual result was 279118000.0, down 53.88% from the prior year.
- Cash from Operations eased to 88897000.0 in Q1 2026 per XENE's latest filing, from 81481000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 16868000.0 in Q2 2022 and troughed at 88897000.0 in Q1 2026.
- A 5-year average of 47149647.06 and a median of 46187000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations rose 11.01% in 2022, then slumped 106.19% in 2025.
- A 5-year view of Cash from Operations shows it stood at 35330000.0 in 2022, then decreased by 0.2% to 35401000.0 in 2023, then plunged by 53.63% to 54385000.0 in 2024, then slumped by 49.82% to 81481000.0 in 2025, then fell by 9.1% to 88897000.0 in 2026.
- Business Quant data shows XENE's Cash from Operations at 88897000.0 in Q1 2026, 81481000.0 in Q4 2025, and 71752000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Xenon Pharmaceuticals | 4.61 Bn | 4.61 Bn | - | -88.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -88.90 Mn |
| Mar 31, 2026 | -88.90 Mn |
| Dec 31, 2025 | -81.48 Mn |
| Dec 31, 2025 | -81.48 Mn |
| Sep 30, 2025 | -71.75 Mn |
| Sep 30, 2025 | -71.75 Mn |
| Jun 30, 2025 | -64.23 Mn |
| Jun 30, 2025 | -64.23 Mn |
| Mar 31, 2025 | -61.65 Mn |
| Mar 31, 2025 | -61.65 Mn |
| Dec 31, 2024 | -54.39 Mn |
| Dec 31, 2024 | -54.39 Mn |
| Sep 30, 2024 | -49.67 Mn |
| Sep 30, 2024 | -49.67 Mn |
| Jun 30, 2024 | -31.15 Mn |
| Jun 30, 2024 | -31.15 Mn |
| Mar 31, 2024 | -46.19 Mn |
| Mar 31, 2024 | -46.19 Mn |
| Dec 31, 2023 | -35.40 Mn |
| Dec 31, 2023 | -35.40 Mn |